BioVersys Presents Phase 2 Data for Antibiotic Candidate BV100 at IDWeek 2026

BioVersys presented Phase 2 clinical data for its antibiotic candidate BV100 at the IDWeek 2026 conference in Washington. The study involved 26 patients with infections from multidrug-resistant bacteria, offering updated insights into the candidate's efficacy and safety. This presentation is part of BioVersys's ongoing development program for BV100.